Specific kinase inhibitors

• US 20060079494A1
• Filed: 09/26/2005
• Published: 04/13/2006
• Est. Priority Date: 09/27/2004
• Status: Abandoned Application

• Current Assignee: Kosan Biosciences, Inc. (Bristol-Myers Squibb Company)
• Original Assignee: Kosan Biosciences, Inc. (Bristol-Myers Squibb Company)
• Inventors: Reid, Ralph C., Santi, Daniel V., Sundermann, Kurt F., Lau, Janice, Hutchinson, C. Richard
• Application Number:
  US11/236,244
• Publication Number:
  US 20060079494A1
• Time in Patent Office: Days
• US Class Current: 514/183
• CPC Class Codes: A61K 31/33 Heterocyclic compounds
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: C07D 493/04 Ortho-condensed systems

Abstract

Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site.

Claims

15. A method for treating a disease or disease condition by administering to a patient in need of treatment for said disease or disease condition a pharmaceutical composition that comprises a compound that specifically inhibits a protein kinase having a cysteine residue (Cys) located between and immediately adjacent to one of two conserved aspartate residues in the ATP-binding site region of said protein kinase, said method comprising contacting said kinase with a compound that forms a Michael adduct with said Cys.

1. A method for inhibiting one or more protein kinases in a mixture or cell, wherein said one or more protein kinases have a cysteine residue (Cys) located between two and immediately adjacent to one conserved aspartate residues in the ATP-binding site of said protein kinase, wherein said mixture comprises additional protein kinases lacking a Cys residue located between two and immediately adjacent to one conserved aspartate residues in an ATP-binding site of said additional protein kinases, said method comprising contacting said kinase with a compound capable of forming a Michael adduct with said Cys residue in said one or more protein kinases under conditions such that said Michael adduct forms between said compound and said Cys residue and results in inhibition of said one or more protein kinases.

2. The method of claim 1, wherein said compound comprises an enone moiety that forms a Michael adduct with said Cys.

3. The method of claim 2, wherein said compound is a resorcylic acid lactone having a cis carbon-carbon double bond at positions 5-6 conjugated to a carbonyl at position 7.

4. The method of claim 2, wherein said compound has a structure I

wherein

R₁ is hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl or optionally substituted heteroaryl moiety;

or R₁ and R₂, when taken together, form an optionally substituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

or R₁ and R₃, when taken together, form an optionally substituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

R₄ is hydrogen or halogen;

R₅ is hydrogen, C₂ to C₄ alkyl, an oxygen protecting group or a prodrug moiety;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0, 1, or 2;

R₇ is, for each occurrence, independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkoxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR₁₂R₁₃, —

X₁(CH₂)_pX₂—

R₁₄, or is alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or −

X₁(CH₂)_pX₂—

R₁₄;

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

X₁ and X₂ are each independently absent, oxygen, NH, or —

N(alkyl), or wherein X₂—

R₁₄ together are N₃ or are a heterocycloaliphatic moiety;

p is an integer from 2 to 10, inclusive; and

R₁₄ is hydrogen or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is —

(C═

O)NHR₁₅, —

(C═

O)OR₁₅, or —

(C═

O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen or an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety;

or R₁₄ is —

SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety;

wherein one or more of R₁₄, R₁₅, and R₁₆ is optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

or R₈ and R₉, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms, said ring being optionally substituted with hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

R₁₀ is hydrogen, hydroxyl, alkoxy, hydroxyalkyl, halogen, or protected hydroxyl;

R₁₁ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

R₂₀ is hydrogen, or R₂₀ and R₂ combine to form a bond;

X is absent or is O, NH, N-alkyl, CH₂, or S;

Y and Z are connected by a single or double bond, with Y being CHR₁₇, O, C═

O, CR₁₇, or NR₁₇ and with Z being CHR₁₈, O, C═

O, CR₁₈, or NR₁₈;

wherein R₁₇ and R₁₈ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic moiety, or R₁₇ and R₁₈ taken together are —

O—

, —

CH₂—

or —

NR₁₉—

, wherein R₁₉ is hydrogen or alkyl;

and the pharmaceutically acceptable salts and derivatives thereof.

5. A method according to claim 4, wherein the compound has a structure according to formula Ia,

wherein

R₉ is hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR₁₂R₁₃, —

X₁(CH₂)_pX₂—

R₁₄, or is alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or —

X₁(CH₂)_pX₂—

R₁₄;

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

X₁ and X₂ are each independently absent, oxygen, NH, or —

N(alkyl), or wherein X₂—

R₁₄ together are N₃ or are a heterocycloaliphatic moiety;

p is an integer from 2 to 10, inclusive; and

R₁₄ is hydrogen or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is —

(C═

O)NHR₁₅, —

(C═

O)OR₁₅, or —

(C═

O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen or an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety;

or R₁₄ is —

SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety;

wherein one or more of R₁₄, R₁₅, and R₁₆ is optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen; and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

6. A method according to claim 4, wherein the compound has a structure according to formula Ib

wherein

R₉ is hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR₁₂R₁₃, —

X₁(CH₂)_pX₂—

R₁₄, or is alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or −

X₁(CH₂)_pX₂—

R₁₄;

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

X₁ and X₂ are each independently absent, oxygen, NH, or —

N(alkyl), or wherein X₂—

R₁₄ together are N₃ or are a heterocycloaliphatic moiety;

p is an integer from 2 to 10, inclusive; and

R₁₄ is hydrogen or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is —

(C═

O)NHR₁₅, —

(C═

O)OR₁₅, or —

(C═

O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen or an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety;

or R₁₄ is —

SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety;

wherein one or more of R₁₄, R₁₅, and R₁₆ is optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen; and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

7. A method according to claim 4, wherein the compound has a structure according to formula Ic

wherein

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkoxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

8. A method according to claim 4, wherein the compound has a structure according to formula Id

wherein

R₁₀ is hydrogen, hydroxyl, alkoxy, hydroxyalkyl, halogen, or protected hydroxyl;

and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

9. A method according to claim 4, wherein the compound has a structure according to formula Ie

R₅ is hydrogen, C₂ to C₅ alkyl, an oxygen protecting group or a prodrug moiety;

and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

10. A method according to claim 4, wherein the compound has a structure according to formula If

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

11. A method according to claim 4, wherein the compound has a structure according to formula Ig:

wherein

R₄ is H or F;

R₈ is H; and

R₉ is selected from the group consisting of

or R₈ and R₉ combine to form

12. The method of claim 1, wherein said mixture is an in vitro reaction mixture.

13. The method of claim 1, wherein said inhibiting step is carried out in a cell.

14. The method of claim 1, wherein said cell is a diseased cell or in diseased tissue.

16. The method of claim 15 wherein said pharmaceutical composition comprises a compound of structure (I)

wherein

R₁ is hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl or optionally substituted heteroaryl moiety;

or R₁ and R₂, when taken together, form an optionally substituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

or R₁ and R₃, when taken together, form an optionally substituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

R₄ is hydrogen or halogen;

R₅ is hydrogen, C₂ to C₄ alkyl, an oxygen protecting group or a prodrug moiety;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0, 1, or 2;

R₇ is, for each occurrence, independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkoxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR12R₁₃, —

X₁(CH₂)_pX₂—

R₁₄, or is alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or —

X₁(CH₂)_pX₂—

R₁₄;

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

X₁ and X₂ are each independently absent, oxygen, NH, or —

N(alkyl), or wherein X₂—

R₁₄ together are N₃ or are a heterocycloaliphatic moiety;

p is an integer from 2 to 10, inclusive; and

R₁₄ is hydrogen or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is —

(C═

O)NHR₁₅, —

(C═

O)OR₁₅, or —

(C═

O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen or an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety;

or R₁₄ is —

SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety;

wherein one or more of R₁₄, R₁₅, and R₁₆ is optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

or R₈ and R₉, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms, said ring being optionally substituted with hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

R₁₀ is hydrogen, hydroxyl, alkoxy, hydroxyalkyl, halogen, or protected hydroxyl;

R₁₁ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

R₂₀ is hydrogen, or R₂₀ and R₂ combine to form a bond;

X is absent or is O, NH, N-alkyl, CH₂, or S;

Y and Z are connected by a single or double bond, with Y being CHR₁₇, O, C═

O, CR₁₇, or NR₁₇ and with Z being CHR₁₈, O, C═

O, CR₁₈, or NR₁₈;

wherein R₁₇ and R₁₈ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic moiety, or R₁₇ and R₁₈ taken together are —

O—

, —

CH₂—

or —

NR₁₉—

, wherein R₁₉ is hydrogen or alkyl;

and the pharmaceutically acceptable salts and derivatives thereof.

17. A method according to claim 16, wherein the compound has a structure according to formula Ia,

wherein

R₉ is hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR₁₂R₁₃, —

X₁(CH₂)_pX₂—

R₁₄, or is alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or —

X₁(CH₂)_pX₂—

R₁₄;

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

X₁ and X₂ are each independently absent, oxygen, NH, or —

N(alkyl), or wherein X₂—

R₁₄ together are N₃ or are a heterocycloaliphatic moiety;

p is an integer from 2 to 10, inclusive; and

R₁₄ is hydrogen or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is —

(C═

O)NHR₁₅, —

(C═

O)OR₁₅, or —

(C═

O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen or an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety;

or R₁₄ is —

SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety;

wherein one or more of R₁₄, R₁₅, and R₁₆ is optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen; and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

18. A method according to claim 16, wherein the compound has a structure according to formula Ib

wherein

R₉ is hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR₁₂R₁₃, —

X₁(CH₂)_pX₂—

R₁₄, or is alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or —

X₁(CH₂)_pX₂—

R₁₄;

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

X₁ and X₂ are each independently absent, oxygen, NH, or —

N(alkyl), or wherein X₂—

R₁₄ together are N₃ or are a heterocycloaliphatic moiety;

p is an integer from 2 to 10, inclusive; and

R₁₄ is hydrogen or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is —

(C═

O)NHR₁₅, —

(C═

O)OR₁₅, or —

(C═

O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen or an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety;

or R₁₄ is —

SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety;

wherein one or more of R₁₄, R₁₅, and R₁₆ is optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen; and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

19. A method according to claim 16, wherein the compound has a structure according to formula Ic

wherein

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkoxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

20. A method according to claim 16, wherein the compound has a structure according to formula Id

wherein

R₁₀ is hydrogen, hydroxyl, alkoxy, hydroxyalkyl, halogen, or protected hydroxyl;

and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

21. A method according to claim 16, wherein the compound has a structure according to formula Ie

R₅ is hydrogen, C₂ to C₅ alkyl, an oxygen protecting group or a prodrug moiety;

and

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

22. A method according to claim 16, wherein the compound has a structure according to formula If:

wherein

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen or an optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl moiety or an N or S protecting group, or R₁₂ and R₁₃, taken together form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms;

each of R₁₂ and R₁₃ being optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, —

NH(alkyl), aminoalkyl, or halogen;

Y and Z are connected by a single or double bond, with Y being CHR₁₇, and with Z being CHR₁₈;

wherein R₁₇ and R₁₈ are hydrogen, or R₁₇ and R₁₈ taken together are —

O—

.

23. A method according to claim 16, wherein the compound has a structure according to formula Ig:

wherein

R₄ is H or F;

R₈ is H; and

R₉ is selected from the group consisting of

or R₈ and R₉ combine to form

24. The method of claim 1, wherein said kinase is selected from the group consisting of AAK1, APEG1 splice variant with kinase domain (SPEG), BMP2K (BIKE), CDKL1, CDKL2, CDKL3, CDKL4, CDKL5 (STK9), ERK1 (MAPK3), ERK2 (MAPK1), FLT3, GAK, GSK3A, GSK3B, KIT (cKIT), MAP3K14 (NIK), MAP3K7 (TAK1), MAPK15 (ERK8), MAPKAPK5 (PRAK), MEK1 (MKK1, MAP2K1), MEK2 (MKK2, MAP2K2), MEK3 (MKK3, MAP2K3), MEK4 (MKK4, MAP2K4), MEK5 (MKK5, MAP2K5), MEK6 (MKK6, MAP2K6), MEK7 (MKK7, MAP2K7), MKNK1 (MNK1), MKNK2 (MNK2, GPRK7), NLK, PDGFR alpha, PDGFR beta, PRKD1 (PRKCM), PRKD2, PRKD3 (PRKCN), PRPF4B (PRP4K), RPS6KA1 (RSK1, MAPKAPK1A), RPS6KA2 (RSK3, MAPKAP1B), RPS6KA3 (RSK2, MAPKAP1C), RPS6KA6 (RSK4), STK36 (FUSED_STK), STYK1, TGFBR2, TOPK, VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4) and ZAK.

25. The method of claim 24, wherein at least two of said kinases are inhibited.

26. The method of claim 24, wherein at least three of said kinases are inhibited.

27. The method of claim 1, wherein said one or more protein kinases are ERK pathway kinases, and at least two of said ERK pathway kinases are inhibited.

28. The method of claim 27, wherein at least four ERK pathway kinases are inhibited.

29. The method of claim 28, wherein said protein kinases are MEK1, MEK2, ERK1, and ERK2.

30. The method of claim 1, wherein said one or more protein kinases inhibited include at least two ERK MAPK cascade pathway kinases and a mitogen receptor kinase.

31. The method of claim 30, wherein the mitogen receptor kinase is selected from the group consisting of:

a VEGF receptor;

a PDGF receptor;

cKIT (the mast cell growth factor receptor);

FLT3 (the receptor for FL, the Flt3 ligand); and

a constitutively activated mutant of a VEGF receptor, a PDGF receptor, cKIT, or FLT3.

32. The method of claim 15, wherein the kinase inhibitor is administered together with a microtubule stabilizing or destabilizing agent.

33. The method of claim 15, wherein the kinase inhibitor is administered together with an Hsp90 inhibitor.

34. The method of claim 33, wherein the HSP90 inhibitor is 17-AAG or 17-DMAG.

35. The method of claim 15, wherein said kinase is selected from the group consisting of PDGFR alpha, PDGFR beta, the VEGF receptors (Flt-1, Flt-4 and Kdr), MEK1/2, and ERK1/2, and said disease is age related macular degeneration or glaucoma.

36. The method of claim 15, wherein said kinase is either Flt-3, c-Kit MEK, ERK, or VEGFR, and said disease is acute myelogenous leukemia.

38. The method of claim 15, wherein said kinase is either wild type c-Kit, a constitutively active c-Kit V816D mutant, MEK1/2 or ERK 1/2, and said disease is mastocytosis.

39. The method of claim 15, wherein said kinase is either MEK1/2, ERK1/2 or Tak1, and said disease is inflammatory bowel disease.

40. The method of claim 39, wherein said inflammatory bowel disease is Crohn'"'"'s disease or ulcerative colitis.

41. The method of claim 15, wherein said kinase is c-Kit, MEK, or ERK, and said disease is an inflammatory syndrome that is influenced by or caused by mast cells.

42. The method of claim 15, wherein said kinase is either MEK1/2 or ERK1/2, and said disease is breast cancer.

43. The method of claim 15, wherein said kinase is either Kdr, c-Kit, MEK1/2 or ERK1/2, and said disease is non-small cell lung cancer.

44. The method of claim 15, wherein said kinase is either PDGFRA, MEK1/2 or ERK1/2 and said disease is ovarian cancer.

45. The method of claim 15, wherein said kinase is either a PDGFR, MEK1/2 or ERK1/2, and said disease is pancreatic cancer.

46. The method of claim 15, wherein said kinase is a kinase activated by a mutant Raf-1 protein kinase, and said disease is prostate cancer.

47. The method of claim 46, wherein said kinase is RSK or MEK/ERK.

48. The method of claim 15, wherein said kinase is either a VEGFR, a PDGFR, MEK1/2, ERK1/2, Tak1, or a kinase that activates the JNK and p38 signaling pathways, and said disease is psoriasis.

49. The method of claim 15, wherein said kinase is either a PDGFR, MEK1/2 or ERK1/2, and said disease is basal cell carcinoma.

50. The method of claim 15, wherein said kinase is either MEK1/2, ERK1/2, Tak1, or a kinase that activates the JNK signaling pathway, and said disease is an inflammatory syndrome.

51. The method of claim 50, wherein said inflammatory syndrome is allergic dermatitis.

52. The method of claim 15, wherein said kinase is a PDGFR, and said disease is pulmonary fibrosis.

53. The method of claim 15, wherein said kinase is either MEK1/2 or ERK1/2, and said disease is a Ras mutant dependent cancer.

54. The method of claim 13, wherein said kinase is either a VEGFR, a PDGFR, MEK1/2 or ERK1/2, and said disease is renal cell carcinoma.

55. The method of claim 15, wherein said kinase is either a PDGFR, MEK1/2, ERK1/2 or Tak1, and said disease is restenosis.

56. The method of claim 15, wherein said kinase is either MEK1/2, ERK1/2 or Tak1, and said disease is rheumatoid arthritis.

57. The method of claim 1, wherein said kinase is a kinase in a cell signaling pathway activated by mutated B-Raf.

58. The method of claim 57, wherein said compound is hypothemycin.

59. The method of claim 15, wherein said kinase is either PDGFRB, PDGFRA, MEK?ERK, or KIT, and said disease is chronic myelomonocytic leukemia, glioblastoma multiforme, GIST, or metastative GIST.

60. The method of claim 15, wherein said kinase is FLT3.

61. The method of claim 15, wherein said disease is acute myeloid leukemia.

62. The method of claim 15, wherein said kinase is either KDR, FLT4, or FLT 1.

63. The method of claim 15, wherein said disease involves angiogenesis.

64. The method of claim 15, wherein said disease involves lymphangiogenis.

65. The method of claim 15, wherein said disease involves the induction of vascular permeability.

66. The method of claim 15, wherein said disease involves inflammation.

67. The method of claim 15, wherein said disease is characterized by the proliferation of cells having mutated B-Raf.

68. The method of claim 67, wherein said compound is hypothemycin.

69. The method of claim 15, wherein said disease is melanoma.

70. The method of claim 69, wherein said compound is hypothemycin.

71. A method in accordance with claim 1, wherein said compound is other than a naturally occurring resorcylic acid lactone, hypothemycin, (5Z)-7-oxozeaneol, Ro-09-2210, and L-783,277.

27-1. The method of claim 15, wherein said kinase is either c-Kit, PDGFR, MEK1/2 or ERK1/2, and said disease is gastrointestinal stromal tumor.

72. A purified and isolated compound having a structure according to formula II:

73. A method for preparing a compound having a structure according to formula II

comprising the step of culturing the organism Hypomyces subiculosus DSM 11931 in a culture medium containing D,L-ethionine in an amount of between about 10 and about 100 mg/L of culture medium.

74. A method according to claim 73, wherein the culture medium contains between about 30 and about 120 g/L sucrose, between about 20 and about 80 g/L corn meal, and about 0 to about 10 g/L yeast extract.